Tbo-filgrastim

DRUG3 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Sidney Kimmel Cancer Center at Thomas Jefferson University

Conditions

Healthy ParticipantsNeutropeniaNon-Hodgkin's LymphomaPlasma Cell Myeloma

Phase 2

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

CompletedNCT02190721

Teva Branded Pharmaceutical Products R&D, Inc.Neutropenia

Start: 2015-05-12End: 2017-04-04Updated: 2021-12-10

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

CompletedNCT03317899

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNon-Hodgkin's Lymphoma, Plasma Cell Myeloma

Start: 2017-10-12End: 2022-11-16Updated: 2025-12-17

Phase 3

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants

TerminatedNCT03029000

Teva Branded Pharmaceutical Products R&D, Inc.Healthy Participants

Start: 2017-08-02End: 2017-10-30Updated: 2022-12-13